研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

12 岁以下接受化疗或造血干细胞移植的儿童米卡芬净预防的回顾性分析。

A Retrospective Analysis of Micafungin Prophylaxis in Children Under 12 Years Undergoing Chemotherapy or Hematopoietic Stem Cell Transplantation.

发表日期:2024 Aug
作者: Breana K Goscicki, Shirley Q Yan, Sherry Mathew, Audrey Mauguen, Nina Cohen
来源: Stem Cell Research & Therapy

摘要:

关于接受化疗或造血干细胞移植的血液恶性肿瘤儿科患者的理想米卡芬净剂量的文献有限。米卡芬净是一种静脉注射棘白菌素,具有抗念珠菌和曲霉菌的活性,与其他抗真菌药物相比具有良好的安全性。我们的目的是评估在我们机构接受预防性米卡芬净疗程的儿科患者的突破性侵袭性真菌感染 (IFI) 率。2011 年 1 月 1 日至 2017 年 7 月 31 日期间进行了一项单中心回顾性研究,以确定接受米卡芬净预防的患者的 IFI 率。根据欧洲癌症研究和治疗组织/侵袭性真菌感染合作组和美国国家过敏和传染病研究所真菌病研究组共识组侵袭性真菌病定义,对疑似 IFI 的患者进行了可能或已证实的感染评估。统计分析是描述性的。共确定了来自 129 名年龄 <12 岁的独特患者的 170 个预防性米卡芬净疗程,中位剂量为每天 3 mg/kg。根据临床、放射学、微生物学和组织病理学标准确定,可能或已证实的突破性 IFI 发生率为 2.4%。使用米卡芬净预防时发现突破性 IFI 发生率较低,这与之前发表的成人造血干细胞移植研究一致。米卡芬净耐受性良好,大多数情况下肝功能测试升高是暂时的,被认为与其他因素有关。版权。儿科药学协会。版权所有。如需许可,请发送电子邮件至:membership@pediatricpharmacy.org。
Literature is limited regarding ideal micafungin dosing in pediatric patients with hematologic malignancies receiving chemotherapy or hematopoietic stem cell transplantation. Micafungin is an intravenous echinocandin with activity against Candida and Aspergillus species and has a favorable safety profile compared with other antifungal classes. Our objective was to evaluate the breakthrough invasive fungal infection (IFI) rate in pediatric patients who received a prophylactic micafungin course at our institution.A single-center, retrospective study was conducted between January 1, 2011, and July 31, 2017, to determine the IFI rate in patients receiving micafungin prophylaxis. Patients with suspected IFI were evaluated for probable or proven infection based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group invasive fungal disease definitions. Statistical analyses were descriptive.A total of 170 prophylactic micafungin courses from 129 unique patients ages <12 years at a median dose of 3 mg/kg daily were identified. The rate of probable or proven breakthrough IFIs was 2.4% as determined by clinical, radiologic, microbiologic, and histopathologic criteria.A low rate of breakthrough IFI was seen with micafungin prophylaxis that is consistent with prior published adult hematopoietic stem cell transplantation studies. Micafungin was well tolerated, with liver function test elevations being transient in most cases and thought to be related to alternative factors.Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org.